After dealing with a deployment problem with glucose monitors earlier this year, interim CEO Jake Leach said improving ...

Q3 2025 Earnings Call Transcript October 30, 2025 DexCom, Inc. beats earnings expectations. Reported EPS is $0.61, ...

Thank you, operator, and welcome to DexCom's Third Quarter 2025 Earnings Call. Our agenda begins with Jake Leach, DexCom's President and Interim CEO, who will summarize our recent highlights and ...

However, the company's financial results have been pretty strong. And if DexCom can keep that up in its next quarterly update ...

DexCom posts Q3 revenue of $1.21 billion, beating estimates and raising 2025 guidance as analysts expect strong sales and margin improvement ahead.

Get key insights from DexCom’s Q3 2025 earnings: robust revenue growth, new product launches, updated guidance, and future opportunities.

DexCom, Inc. DXCM reported third-quarter 2025 adjusted earnings per share (EPS) of 61 cents, which beat the Zacks Consensus ...

DexCom’s Fair Value Estimate has recently been revised downward, moving modestly from $102.08 to $100.54 per share. This change reflects subtle shifts in analyst sentiment. While the company still ...

DexCom, Inc. (NASDAQ:DXCM) is one of the Best Long Term Growth Stocks to Buy Now. On September 19, William Blair analyst Brandon Vazquez maintained their bullish stance on the company’s stock, giving ...

The deal concerns the connectivity between Glooko's self-titled mobile app and Dexcom's continuous glucose monitoring (CGM) devices. Currently, Dexcom device users upload CGM data to the Glooko app ...

An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include ...